Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 191

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis

Open access
Rotinen, Mirja, You, Sungyong, Yang, Julie, Coetzee, Simon G., Reis-Sobreiro, Mariana, Huang, Wen-Chin, Huang, Fangjin, Pan, Xinlei, Yáñez, Alberto, Hazelett, Dennis J., Chu, Chia-Yi, Steadman, Kenneth, Morrissey, Colm M., Nelson, Peter S., Corey, Eva, Chung, Leland W. K., Freedland, Stephen J., Di Vizio, Dolores, Garraway, Isla P., Murali, Ramachandran, Knudsen, Beatrice S., Freeman, Michael R. · 2018 · Nature Medicine

Abstract

Treatment of prostate cancer (PC) by androgen suppression promotes the emergence of aggressive variants that are androgen receptor (AR) independent. Here we identify the transcription factor ONECUT2 (OC2) as a master regulator of AR networks in metastatic castration-resistant prostate cancer (mCRPC). OC2 acts as a survival factor in mCRPC models, suppresses the AR transcriptional program by direct regulation of AR target genes and the AR licensing factor FOXA1, and activates genes associated with neural differentiation and progression to lethal disease. OC2 appears active in a substantial subset of human prostate adenocarcinoma and neuroendocrine tumors. Inhibition of OC2 by a newly identified small molecule suppresses metastasis in mice. These findings suggest that OC2 displaces AR-dependent growth and survival mechanisms in many cases where AR remains expressed, but where its activity is bypassed. OC2 is also a potential drug target in the metastatic phase of aggressive PC. ONECUT2 is a targetable transcription factor that antagonizes androgen receptor signaling and drives androgen independence and neuroendocrine differentiation in castration-resistant prostate cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-018-0241-1

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 191

Metadata

Authors
Rotinen, M., You, S., Yang, J., Coetzee, S. G., Reis-Sobreiro, M., Huang, W.-C., Huang, F., Pan, X., Yáñez, A., Hazelett, D. J., Chu, C.-Y., Steadman, K., Morrissey, C. M., Nelson, P. S., Corey, E., Chung, L. W. K., Freedland, S. J., Di Vizio, D., Garraway, I. P., Murali, R., Knudsen, B. S., & Freeman, M. R.
Venue
Nature Medicine
Published
2018-11-26
Volume
24
Issue
12
Pages
1887-1898
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2900452086
Cited by
191
References
10
FWCI
12.17
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. https://app.cochat.ai/papers/10.1038/s41591-018-0241-1
The paper
Rotinen, M., You, S., Yang, J., Coetzee, S. G., Reis-Sobreiro, M., Huang, W.-C., Huang, F., Pan, X., Yáñez, A., Hazelett, D. J., Chu, C.-Y., Steadman, K., Morrissey, C. M., Nelson, P. S., Corey, E., Chung, L. W. K., Freedland, S. J., Di Vizio, D., Garraway, I. P., . . . Freeman, M. R. (2018). ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. Nature Medicine. https://doi.org/10.1038/s41591-018-0241-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.